74 related articles for article (PubMed ID: 16705127)
1. Re: Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene.
Das UN
J Natl Cancer Inst; 2006 May; 98(10):718; author reply 718-20. PubMed ID: 16705127
[No Abstract] [Full Text] [Related]
2. Effect of gamma-linolenic acid on the transcriptional activity of the Her-2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Colomer R; Lupu R
J Natl Cancer Inst; 2005 Nov; 97(21):1611-5. PubMed ID: 16264182
[TBL] [Abstract][Full Text] [Related]
3. [ERBB2/HER2: from molecular to clinical oncology].
Khanson KP; Imianitov EN
Vopr Onkol; 2002; 48(2):137-45. PubMed ID: 12227060
[No Abstract] [Full Text] [Related]
4. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
5. The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells.
Menendez JA; Vellon L; Lupu R
Int J Gynecol Cancer; 2006; 16(1):219-21. PubMed ID: 16445636
[No Abstract] [Full Text] [Related]
6. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
[TBL] [Abstract][Full Text] [Related]
7. Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu.
Shiu LY; Liang CH; Chang LC; Sheu HM; Tsai EM; Kuo KW
Biosci Rep; 2009 Feb; 29(1):35-45. PubMed ID: 18699774
[TBL] [Abstract][Full Text] [Related]
8. The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines.
Lyu MA; Kurzrock R; Rosenblum MG
Biochem Pharmacol; 2008 Feb; 75(4):836-46. PubMed ID: 18082672
[TBL] [Abstract][Full Text] [Related]
9. Polysomy 17 and HER-2 amplification: true, true, and unrelated.
Rosenberg CL
J Clin Oncol; 2008 Oct; 26(30):4856-8. PubMed ID: 18794542
[No Abstract] [Full Text] [Related]
10. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression.
Henson ES; Hu X; Gibson SB
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):845-53. PubMed ID: 16467098
[TBL] [Abstract][Full Text] [Related]
11. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
12. The distinctive nature of HER2-positive breast cancers.
Burstein HJ
N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
[No Abstract] [Full Text] [Related]
13. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
Ross JS; Gray GS
Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
[TBL] [Abstract][Full Text] [Related]
14. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
15. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab.
Biroccio A; D'Angelo C; Jansen B; Gleave ME; Zupi G
J Cell Physiol; 2005 Aug; 204(2):463-9. PubMed ID: 15685647
[TBL] [Abstract][Full Text] [Related]
16. Cell line standards to reduce HER-2/neu assay variation and the potential of automated image analysis to provide more accurate cut points for predicting clinical response to trastuzumab.
Jasani B; Miller K
Am J Clin Pathol; 2005 Feb; 123(2):314; author reply 314-5. PubMed ID: 15842059
[No Abstract] [Full Text] [Related]
17. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
18. New insights into oncogene addiction found.
Garber K
J Natl Cancer Inst; 2007 Feb; 99(4):264-5, 269. PubMed ID: 17312299
[No Abstract] [Full Text] [Related]
19. Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells.
Abuharbeid S; Apel J; Sander M; Fiedler B; Langer M; Zuzarte ML; Czubayko F; Aigner A
Biochem Biophys Res Commun; 2004 Aug; 321(2):403-12. PubMed ID: 15358191
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab and chemotherapeutics: drug interactions and synergies.
Pegram MD; Lopez A; Konecny G; Slamon DJ
Semin Oncol; 2000 Dec; 27(6 Suppl 11):21-5; discussion 92-100. PubMed ID: 11236023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
